Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2017 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at Stifel 2017 Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...
November 07, 2017 08:05 ET | Source: Genocea Biosciences, Inc.

Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017

- ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types - - ATLAS also identifies unique tumor-associated antigen response signatures ...
November 02, 2017 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Reports Third Quarter 2017 Financial Results

- SITC presentation to highlight ATLAS™ ability in neoantigen selection - - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q1 2018 - - Conference call today at 9 am ET - CAMBRIDGE,...
October 26, 2017 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET

CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a...
September 25, 2017 16:30 ET | Source: Genocea Biosciences

Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines

- Superior ATLASTM platform for neoantigen selection (1) - - Exploring strategic alternatives for GEN-003 -- Announces corporate restructuring - CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) --...
September 20, 2017 08:00 ET | Source: Genocea Biosciences

Genocea to Present at Cantor Fitzgerald Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens,...
August 09, 2017 08:00 ET | Source: Genocea Biosciences

Genocea Biosciences Reports Second Quarter 2017 Financial Results

- Recently reported positive top-line 12-month Phase 2b data for GEN-003 in genital herpes -- IND filing for neoantigen cancer vaccine, GEN-009, expected in Q4 2017 - CAMBRIDGE, Mass., Aug. 09, 2017...
July 28, 2017 08:00 ET | Source: Genocea Biosciences

Genocea Biosciences to Highlight GEN-003 Clinical Data at the 42nd Annual International Herpesvirus Workshop

- Pre-Conference symposium, posters, and oral presentation will highlight GEN-003 Phase 2b clinical data - CAMBRIDGE, Mass., July 28, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc....
July 24, 2017 07:00 ET | Source: Genocea Biosciences

Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes

- Statistically significant result on expected Phase 3 primary endpoint with Phase 3 dose -- Positive results on multiple secondary clinical endpoints -- Potentially the first new treatment in more...
June 26, 2017 08:00 ET | Source: Genocea Biosciences

Genocea Added to Russell 3000® and Russell 2000® Indices

CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that...